| Previous close | 2.2500 |
| Open | 2.2500 |
| Bid | 2.1000 |
| Ask | 4.6000 |
| Strike | 7.50 |
| Expiry date | 2024-10-18 |
| Day's range | 2.2500 - 2.2500 |
| Contract range | N/A |
| Volume | |
| Open interest | 6 |
Business WireOmniAb Announces Publication of Scientific Paper on Heavy Chain-Only Single-Domain Antibody Chicken Platform in the Journal of Immunology
EMERYVILLE, Calif., June 03, 2024--OmniAb, Inc. (NASDAQ: OABI) today announced the publication of a peer-reviewed paper titled "Chickens with a Truncated Light Chain Transgene Express Single-Domain H Chain-Only Antibodies" in the Journal of Immunology demonstrating that chickens can be genetically engineered to produce functional heavy chain-only single-domain antibodies.
Simply Wall St.Are Investors Undervaluing OmniAb, Inc. (NASDAQ:OABI) By 34%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, OmniAb fair value estimate is US$6.77 Current share price of...
- Business Wire
OmniAb to Participate in the Jefferies Global Healthcare Conference
EMERYVILLE, Calif., May 20, 2024--OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating at the Jefferies Global Healthcare Conference, being held June 4-6, 2024 at the Marriott Marquis in New York City. Management will be presenting a corporate overview on Wednesday, June 5th at 8:00 a.m. Eastern time and will be holding one-on-one meetings with investors.
